Some embodiments of the present disclosure include a cream for treating the skin. The cream may include gray clay kaolin; sodium lauryl ether sulfate; blue tartarzine; sodium chloride; menthol; metabisulfite sodium; gelatin; mineral oil; olive oil; oil of cloves; water; green tea; honey; and aloe vera. The cream may also include talc, apple perfume, vitamin E, vitamin D, vitamin C, vitamin B2, vitamin B5, vitamin H, vitamin B6, and vitamin D. The cream may also include fatty acids.

Some embodiments of the present disclosure include a cream for treating the skin. The cream may include gray clay kaolin; sodium lauryl ether sulfate; blue tartarzine; sodium chloride; menthol; metabisulfite sodium; gelatin; mineral oil; olive oil; oil of cloves; water; green tea; honey; and aloe vera. The cream may also include talc, apple perfume, vitamin E, vitamin D, vitamin C, vitamin B2, vitamin B5, vitamin H, vitamin B6, and vitamin D. The cream may also include fatty acids.

Methods and compositions for modulating JNK activity and stimulating efferocytosis in a cell or patient are described. Therapeutic modified collagens comprising a plurality of proteins characterized by Table 1 for use as JNK modulators are also described.

A tooth dentin, pulp or pulp tissue composition for treating or preventing a disease, disorder, or symptom of a tooth dentin and/or pulp or pulp tissue includes: (a) an integrin binding fragment of Laminin, the Laminin being selected from the group consisting of Laminin 511 and Laminin 411, the integrin binding fragment comprising an integrin-binding domain of the Laminin; and (b) a mixture of odontoblast and mineralized nodules secreted from the odontoblast. A coating density of the integrin binding fragment is 1 to 8 ?g/cm.sup.2. The material (b) has been mixed with the material (a) in the composition so as to form pulp capping applicable to a tooth, such that the composition is able to treat or prevent the disease, disorder or symptom of the tooth dentin and/or pulp tissue including dental caries when applied to the tooth.

The invention relates to a free glycine source for use in inducing tolerance against an allergen, or preventing the development of allergy in a human or other mammal. The invention further relates to a composition comprising protein, fat and carbohydrates with at least 7 en % protein and at least 60 mg free glycine source per gram protein, preferably at least 70 mg glycine per gram protein. Said free glycine source is preferably the free amino acid glycine, a salt of the free amino acid glycine, or a combination thereof; the protein can be intact protein, hydrolysed protein, peptides, free amino acids, salts of amino acids, or combinations thereof.

The present invention relates to a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. The invention further relates to methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes.

Hydrolyzed collagen types I, II, and V powder compositions, method of preparing the compositions, and use of the compositions in treating a variety of ailments. The compositions are topically or orally administered to an individual at a daily dosage between 1500 mg and 2000 mg.

This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.

The method of making a hydrolyzed collagen gel is a manufacturing method for producing a hydrolyzed collagen gel to be used as a topical wound treatment. A first volume of purified water is initially heated to a temperature ranging from about 71 C. to about 77 C., and a hydrolyzed type I collagen powder is then mixed into the heated purified water to form a first mixture. An additive is mixed into the first mixture to form a second mixture, where the additive may be native collagen, at least one amino acid, least one therapeutic agent, gelatin, whey, hydrolyzed whey, polysulfated glycosaminoglycan, a glucosamine salt, glutamine, glycosaminoclycans, zinc, silver oxide alginates, cellulose, honey, mushroom extract and combinations thereof. A second volume of purified water is then added to the second mixture to form the hydrolyzed collagen gel product. Mixing is performed as a continuous, recirculating, temperature-monitored and temperature-maintained process.

Cyclized peptides derived from the hyaluronan binding region of RHAMM are provided. Pharmaceutical compositions and methods for using the peptides and pharmaceutical compositions are also provided.